Radiaction Medical has raised US$12.6 million in Series C2 funding led by US private equity fund InnovaHealth Partners with participation from additional co-investors and has announced the election of Christopher Barys to serve on its Board of Directors.
The novel Radiaction system is the first and only advanced technology to proactively block radiation at the source, providing comprehensive, head-to-toe radiation protection to the entire interventional team while allowing unencumbered patient care, access, and service, the company says in a press release.
Barys joins the organisation with more than 30 years of medical device sales, marketing, and business experience, including leading growth and innovation within the cardiac catheterisation and image-guided spaces.
Barys said: “I am thrilled to be a part of Radiaction’s mission to provide advanced radiation protection to the entire procedural staff. Now more than ever, the medical community needs innovative solutions to pressing systemic problems. Radiaction is disrupting the industry for the better. I am looking forward to supporting Radiaction in bringing its radiation reduction solution to every catheterisation lab in the USA and abroad.”
Jonathan Yifat, Radiaction CEO, adds: “This current financing round is a significant step forward, one that enables us to expand our reach further, lead with exceptional customer support, and provide this essential technology to protect those who care for patients.
“The addition of Christopher Barys is a tremendous asset to the strategic composition of our Board of Directors. Chris has a proven track record of market development and growth within the interventional space we aim to serve. He brings a keen eye for strategic opportunities and will help guide our company through its next stages of growth.”
